"I'd hate for people to just assume, 'Oh, this is another cancer vaccine, therefore it's going to fail like so many others have failed in big clinical trials,'" Gritstone Oncology Inc. CEO Andrew Allen told BioWorld. Investors in the company's individualized, tumor-specific neoantigen strategy – able to sort the plethora of mutations in cancer for key ones – apparently made no such assumption, as they put a handsome $92.7 million into the series B round.